Welcome to the Fall 2024 Notable New Drugs Report
New treatments target relatively small, hard-to-treat patient populations with big drug spend.
This edition of the report showcases:
- A first-in-class treatment for both A and B hemophilia which can reduce the frequency of bleeding episodes.
- A new addition to standard breast cancer therapy with improved outcomes for people with HR-positive breast cancer.
- A new drug to treat a rare congenital heart disease can reduce the risk of death by 57%.
Related healthcare insights
Article
An estimated 23% of the workforce will be over age 65 by 2050 – but what does that mean for my drug plan?
Article
Get your guide to the evolving health care regulatory landscape and see what’s coming as lawmakers debate 600+ new bills impacting PBMs.
Article
Another busy year in pharmacy is coming. Read about top stories in GLP-1s, biosimilars, top spend classes, key regulations and innovations.